Navigation Links
Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial

SAN MARINO, Calif., Feb. 12 /PRNewswire/ -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is designed to seek-out and destroy metastatic cancers that are resistant to chemotherapy and which have spread throughout the body. The new website is designed to inform the general public of the basic platform biotechnologies that enable the nano-medicine to flow beyond the finest catheter, beyond the reach of the most gifted surgeon, to the very fabric of nature -- and to update prospective patients as to the current availability of Rexin-G in an increasing number of clinical trials conducted in the U.S. and the Republic of the Philippines.

The Rexin-G video is an animated tour-de-force of Science Communications. Winning both the Bronze Telly Award for film and video productions and the Platinum Aurora Award (Best of Show) for excellence in independent film-making, the Rexin-G video is a triumph of Art in the service of Science, in the service of Medicine. As one watches the artful collapsing of a tumor under the onslaught of the targeted genetic medicine, it is interesting to note that the complex mechanisms of cellular apoptosis, focal necrosis, and anti-angiogenesis were beautifully "translated" by a Native American artist/programmer by visualizing and digitizing time-lapse photography that revealed the collapsing of a pumpkin in a field. Likewise, the interactive booklet is a magical work of electronic storytelling, utilizing video stills, laser cut-outs, and other curious means to take the reader/viewer into the center of the cell to view, and to treat, cancer from the inside.

By focusing on informing society and the cancer patient of these newly-emergent, enabling biotechnologies, the accessibility of published scientific literature, and the availability of ongoing clinical trials, Epeius Biotech hopes to establish a new standard of corporate conduct and communications that recognizes the reason and intelligence of each and every cancer patient, the power and grace of an inspired medical mission, and the true value of service in an otherwise graceless age.

Rexin-G is currently in clinical trials in the U.S. It has been granted Orphan Drug Status by the U.S. FDA for three cancer indications: (i) Pancreatic cancer, (ii) Soft Tissue Sarcoma, and (iii) Osteosarcoma. Rexin-G has recently been approved in the Philippines for the treatment of all solid tumors that are refractory to standard chemotherapy. For general information please visit and for detailed information regarding patient eligibility for current clinical trials contact Dr. Erlinda M. Gordon, Medical Director (

*(LOGO 72dpi:

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

SOURCE Epeius Biotech
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
2. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
3. Max Muscle Introduces First-Ever Probiotics Protein Bar
4. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
5. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
6. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
8. World's First Website for Patients to Share Diagnostic-Quality Medical Images
9. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
10. BioComp Pharma Launches First Generic Drug for Tindamax(R)
11. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
Post Your Comments:
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf ... the 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section ... her work with turfgrass. , Clarke, of Iselin, N.J., is an extension ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... But unless it is bound to proteins, copper is also toxic to cells. ... at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
Breaking Biology Technology:
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... announced a partnership with 2XU, a global leader ... deliver a smart hat with advanced bio-sensing technology. ... other athletes to monitor key biometrics to improve ... strategic partnership, the two companies will bring together the ...
Breaking Biology News(10 mins):